Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer

Recruiting now · Phase 1

Conditions studied: Metastatic Castration-resistant Prostate Cancer, Advanced Prostate Adenocarcinoma, PSCA-positive Prostate Cancer, PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer

In brief

This example Phase 1 study is designed to evaluate the safety, tolerability, feasibility, and preliminary anti-tumor activity of ETB-DualNK-01, an allogeneic dual-target PSMA/PSCA CAR-NK cell therapy, in adults with metastatic castration-resistant prostate cancer (mCRPC). Part A uses dose escalation to determine the maximum tolerated dose and/or recommended Phase 2 dose. Part B expands at the selected dose in biomarkerconfirmed disease.

Key facts

Study ID

NCT07641049

Run by

Beijing Biotech

People needed

36

Starts

2026-03-02

Expected to finish

2028-06-17

Last updated by the study team

2026-06-11

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Male participant age 18 years or older.
• Histologically or cytologically confirmed prostate adenocarcinoma with metastatic castration-resistant disease.
• Disease progression by PCWG3 while maintaining castrate testosterone (<50 ng/dL) with ongoing androgen deprivation therapy or prior orchiectomy.
• Documented PSMA and/or PSCA expression by a validated tumor assay; PSMA PET may support target confirmation when applicable.
• Prior progression on at least one androgen receptor pathway inhibitor such as abiraterone, enzalutamide, apalutamide, or darolutamide; prior taxane, PARP inhibitor, radioligand therapy, or checkpoint inhibitor is allowed.
• ECOG performance status 0 or 1.
• Adequate hematologic, renal, hepatic, cardiac, and pulmonary function per protocol laboratory thresholds.
• At least one measurable lesion by RECIST 1.1 or evaluable bone-predominant disease by PCWG3.
• Life expectancy of at least 12 weeks.
• Ability to understand and sign informed consent and willingness to provide required blood and tissue samples.

You may not qualify if…

• Active central nervous system metastases or leptomeningeal disease.
• Dominant small-cell or neuroendocrine prostate cancer histology.
• Prior gene-modified cellular therapy within 6 months before lymphodepletion, or prior allogeneic transplant requiring ongoing systemic immunosuppression.
• Active autoimmune disease requiring systemic treatment or chronic immunosuppression; systemic corticosteroid use greater than 10 mg prednisone equivalent daily within 7 days of lymphodepletion.
• Uncontrolled infection, including uncontrolled hepatitis B, hepatitis C, or HIV infection.
• Clinically significant cardiovascular disease, symptomatic arrhythmia, recent myocardial infarction, or uncontrolled heart failure.
• Unresolved grade 2 or higher toxicity from prior anticancer therapy, except alopecia, stable endocrinopathy, or other protocol-approved exceptions.
• Another active malignancy requiring systemic treatment.
• Any medical, psychiatric, or laboratory abnormality that, in the investigator's judgment, would increase risk or interfere with study interpretation.

Where it is running

• Peking University Shenzhen Hospital — Shenzhen, Guangdong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.